AN2 Therapeutics, Inc. (ANTX)
4.55
+0.07
(+1.56%)
USD |
NASDAQ |
May 19, 16:00
AN2 Therapeutics EPS Diluted (Quarterly) : -0.2944 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Relmada Therapeutics, Inc. | -0.22 |
| Corcept Therapeutics, Inc. | -0.2988 |
| Assertio Holdings, Inc. | -2.931 |
| Johnson & Johnson | 2.141 |
| Eli Lilly & Co. | 8.255 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -10.03M |
| Total Expenses (Quarterly) | 10.03M |
| Enterprise Value | 78.59M |
| Earnings Yield | -24.27% |
| Normalized Earnings Yield | -24.27 |